HEPATIC HOMING OF MONONUCLEAR INFLAMMATORY CELLS (MC) ISOLATED FROM THE LIVERS OF MICE DURING CHRONIC GRAFT-VS-HOST DISEASE (CGVHD) - KINETICS AND LOCALIZATION

被引:0
|
作者
HOWELL, CD
YODER, T
VIERLING, JM
机构
[1] UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262
[2] VET ADM MED CTR,DEPT MED,DENVER,CO 80220
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:A549 / A549
页数:1
相关论文
共 31 条
  • [21] ROLE OF INFILTRATING CD4 T-CELLS IN THE PATHOGENESIS OF NONSUPPURATIVE DESTRUCTIVE CHOLANGITIS (NSDC) IN MURINE CHRONIC GRAFT-VS-HOST DISEASE (CGVHD)
    HU, KO
    FREILICH, B
    YU, CH
    VIERLING, JM
    HEPATOLOGY, 1993, 18 (04) : A171 - A171
  • [22] Chemokine receptor (CCR) expression by biliary epithelial cells (BECS) during evolution of non-suppurative destructive cholangitis (NSDC) murine chronic graft-vs-host disease (CGVHD).
    Wang, HM
    Hreha, GI
    Vierling, JM
    HEPATOLOGY, 2001, 34 (04) : 355A - 355A
  • [23] MONONUCLEAR-CELLS REGULATE IN-VITRO MAST-CELL AND FIBROBLAST FUNCTIONAL-ACTIVITY IN MURINE AND HUMAN CHRONIC GRAFT-VS-HOST DISEASE
    LEVISCHAFFER, F
    SEGAL, V
    BARAK, V
    RUBINCHIK, E
    CONDIOTTI, R
    NAGLER, A
    EXPERIMENTAL HEMATOLOGY, 1994, 22 (08) : 825 - 825
  • [24] SUCCESSFUL PRODUCTION OF T-T HYBRIDOMAS FROM T-CELLS ACTIVATED INVIVO DURING GRAFT-VS-HOST DISEASE
    LEIBNITZ, RR
    LIPSKY, PE
    THIELE, DL
    FASEB JOURNAL, 1992, 6 (04): : A1405 - A1405
  • [25] Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Glucocorticoid-Refractory chronic Graft-vs-Host Disease (cGVHD): Primary findings from the phase 3, randomized REACH3 study
    Zeiser, R.
    Polverelli, N.
    Ram, R.
    Hashmi, S.
    Chakraverty, R.
    Langmuir, P.
    Hollaender, N.
    Gowda, M.
    Stefanelli, T.
    Lee, S. J.
    Teshima, T.
    Locatelli, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 65 - 66
  • [26] Evolution of inflammation cytokine production and non-suppurative destructive cholangitis (NSDC) resulting in apoptosis of biliary epithelial cells (BEC) in murine chronic graft-vs-host disease (CGVHD) is consistent with in vitro studies.
    Hreha, GI
    Ouyang, Y
    Vierling, JM
    HEPATOLOGY, 2000, 32 (04) : 202A - 202A
  • [27] Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
    Zeiser, Robert
    Polverelli, Nicola
    Ram, Ron
    Hashmi, Shahrukh K.
    Chakraverty, Ronjon
    Flowers, Mary E. D.
    Dawkins, Fitzroy
    Hollaender, Norbert
    Gowda, Maanasa
    Stefanelli, Tommaso
    Lee, Stephanie J.
    Teshima, Takanori
    Locatelli, Franco
    BLOOD, 2020, 136
  • [28] ALLOSUPPRESSOR AND ALLOHELPER T-CELLS IN ACUTE AND CHRONIC GRAFT-VS-HOST DISEASE .5. F1-MICE WITH SECONDARY CHRONIC GVHD CONTAIN F1-REACTIVE ALLOHELPER BUT NO ALLOSUPPRESSOR T-CELLS
    PALS, ST
    GLEICHMANN, H
    GLEICHMANN, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 159 (02): : 508 - 523
  • [29] Decreased interleukin-12 (IL-12) mRNA expression and protein production from activated cord (C) vs adult (A) mononuclear cells (MNC): Possible role in the decreased incidence of graft-vs-host disease (GVHD) post cord blood (CB) transplant.
    Lee, S
    Suen, Y
    Knoppel, E
    Cairo, MS
    BLOOD, 1995, 86 (10) : 640 - 640
  • [30] BONE-MARROW TRANSPLANTATION ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS .5. PROTECTION OF MICE FROM LETHAL GRAFT-VS-HOST DISEASE BY PRETREATMENT OF DONOR CELLS WITH MONOCLONAL ANTI-THY-1.2 COUPLED TO THE TOXIN RICIN
    VALLERA, DA
    YOULE, RJ
    NEVILLE, DM
    KERSEY, JH
    JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (03): : 949 - 954